Back to top
more

Labcorp Holdings Inc. (LH)

(Real Time Quote from BATS)

$263.63 USD

263.63
109,120

+3.67 (1.41%)

Updated Aug 8, 2025 11:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (97 out of 244)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

3 Reasons to Retain Integer Holdings (ITGR) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and solid foothold in the broader MedTech space.

Zacks Equity Research

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, contraction in gross margin is a woe.

Zacks Equity Research

Here's Why You Should Hold on to Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors are optimistic about Bruker's (BRKR) growth in the BioSpin Group and CALID Group.

Zacks Equity Research

Illumina (ILMN) Ties Up With Syapse to Evaluate Biomarker Testing

by Zacks Equity Research

Illumina's (ILMN) recent collaboration will explore the real-world uptake and actionability of comprehensive genomic profiling in patients with advanced cancer.

Zacks Equity Research

Here's Why You Should Retain LHC Group (LHCG) Stock Now

by Zacks Equity Research

LHC Group (LHCG) continues to benefit from strategic deals and a broad array of services.

Zacks Equity Research

Here's Why You Should Add Omnicell (OMCL) Stock for Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) on strength in medication management and adherence automation solutions.

Zacks Equity Research

3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.

Zacks Equity Research

Here's Why You Should Hold on to NextGen (NXGN) Stock Now

by Zacks Equity Research

NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. Intense competition is a headwind.

Zacks Equity Research

LabCorp (LH) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

LabCorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

3 Reasons to Add McKesson (MCK) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about McKesson (MCK) owing to its robust Biologics business.

Zacks Equity Research

Quidel's (QDEL) Antigen Tests Successful in Omicron Detection

by Zacks Equity Research

The success of Quidel's (QDEL) antigen tests against Omicron is expected to lead to better access to affordable COVID-19 testing.

Zacks Equity Research

PacBio's (PACB) New Surveillance Kit Successful Against Omicron

by Zacks Equity Research

PacBio's (PACB) latest surveillance kit is expected to aid public health entities to better answer critical questions about Omicron and its impacts.

Zacks Equity Research

AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?

by Zacks Equity Research

Investors are optimistic about AMN Healthcare's (AMN) broad array of services.

Zacks Equity Research

AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.

Zacks Equity Research

OPKO's (OPK) RAYALDEE Favored by Trial Data for COVID Patients

by Zacks Equity Research

Latest trial results indicate that using OPKO's (OPK) RAYALDEE may improve vitamin D status for faster relief from respiratory symptoms for COVID-19 patients.

Zacks Equity Research

LabCorp (LH) to Expand Oncology Portfolio With Latest Buyout

by Zacks Equity Research

LabCorp's (LH) acquisition of PGDx will position the company at the forefront of driving better patient outcomes in oncology.

Zacks Equity Research

Are These Medical Stocks Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Has Quest Diagnostics (DGX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Quest Diagnostics (DGX) and LabCorp (LH) have performed compared to their sector so far this year.

Zacks Equity Research

LH vs. WST: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

LH vs. WST: Which Stock Is the Better Value Option?

Zacks Equity Research

Quidel (QDEL) Inks Buyout Deal to Solidify Its Diagnostics Arm

by Zacks Equity Research

Quidel's (QDEL) latest buyout is expected to expand its point-of-care diagnostics portfolio as well as geographic footprint.

Sandip Chakraborty headshot

5 Momentum Stocks Bargain Hunters Would Love Chasing

by Sandip Chakraborty

Given the prevailing sentiment in the market, Academy Sports (ASO), Avis Budget (CAR), Laboratory Corporation (LH), Penske Automotive (PAG) and West Fraser (WFG) are expected to give handsome returns to momentum investors.

Zacks Equity Research

Hologic (HOLX) to Meet High Testing Demand With Panther Trax

by Zacks Equity Research

Hologic's (HOLX) Panther Trax scalable solutions will meet the needs of today's laboratories, enabling them to expand operational capacity and testing volumes.

Zacks Equity Research

BD's (BDX) Latest Buyout to Enhance its Digital Capabilities

by Zacks Equity Research

BD's (BDX) acquisition of Scanwell is expected to significantly transform its at-home solutions both at present and in the future.

Zacks Equity Research

Here's Why You Should Retain Merit Medical (MMSI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its potential in the Peripheral Intervention arm and a strong product portfolio.

Zacks Equity Research

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient-monitoring.